Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Lectins Stories

2013-04-17 08:29:13

-- Orphan Drug Designation Could Provide Financial Incentives and Faster Regulatory Review -- SEATTLE, April 17, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed an Application for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP?2) program, for use in the treatment of atypical hemolytic uremic syndrome...

2013-04-10 08:31:11

Galectin-3 test may help physicians identify patients at highest risk for a worse prognosis, including re-hospitalization and death, allowing them to tailor the level of care to individual patient needs1 ABBOTT PARK, Ill., April 10, 2013 /PRNewswire/ -- Abbott today announced CE Marking (Conformite Europeenne) for the ARCHITECT Galectin-3 assay, a test to aid doctors in assessing the prognosis of patients diagnosed with chronic heart failure (HF). The test was developed in...

2013-04-04 08:28:30

Former Silicon Valley Leaders Say Atlanta Emerging as "Silicon Valley for Biotech" and Curing Big Diseases NORCROSS, Ga., April 4, 2013 /PRNewswire/ -- Gilbert Amelio, former CEO of Apple, and Rod Martin, former counsel to PayPal, both on the Board of Directors of Galectin Therapeutics (NASDAQ: GALT) authored an opinion piece in today's Atlanta Journal Constitution discussing the future of Atlanta as the emerging Silicon Valley for changing the world by curing the big diseases, and...

2013-03-28 08:27:59

-- European Clinical Trial Application Submission Expected in the Second Quarter of 2013 -- SEATTLE, March 28, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced data from toxicology studies evaluating OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program. In non-human primates and rodents, there were no drug-related findings in the toxicology assessments, including gross pathology, histopathology...

2013-02-07 08:27:06

SEATTLE, Feb. 7, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced data from toxicology studies evaluating OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin associated serine protease-2 (MASP-2) program. Based on the data from these nonhuman primate studies, OMS721 is expected to be delivered subcutaneously to patients at a convenient dosing schedule of weekly, bi-monthly or even less frequently. Omeros is now analyzing additional data and...

2012-11-20 08:26:22

SANTA ROSA, Calif., Nov. 20, 2012 /PRNewswire/ -- Cardiovascular disease will kill nearly 2.5 million people in the United States this year, according to the Centers for Disease Control. Over time, inflammation, collagen deposition and scar tissue formation can cause blood vessels to stiffen, a process called vascular fibrosis. Though researchers have known that the hormone aldosterone (Aldo) plays a role in this process, the precise mechanisms have been poorly understood. Now, an...

2012-10-16 15:23:55

CHICAGO, Oct. 16, 2012 /PRNewswire/ -- Early symptoms of the contaminated steroid injection present similar to the flu. TorHoerman Law warns that it is imperative for those exposed to the shot to act promptly in determining exposure. Treatment of this rare form of meningitis is critical. Following are 6 tips in determining potential exposure to meningitis. If the shot was administered between May 21, 2012 and September 26, 2012, there may be exposure. The medical clinics...

2012-09-19 02:30:49

OKLAHOMA CITY, Sept. 19, 2012 /PRNewswire/ -- Selexys Pharmaceuticals, Corp., announced today that it has successfully completed a $23 million Series A equity financing, led by MPM Capital. Additionally, Selexys entered into an agreement with Novartis Pharmaceuticals whereby Novartis has been granted an exclusive option to acquire Selexys and its lead asset, the anti-P-selectin antibody SelG1, following the successful completion of a Phase 2 clinical study in patients with sickle cell...

2012-09-14 02:23:56

GRONINGEN and WAGENINGEN, Netherlands, Sept. 14, 2012 /PRNewswire/ -- Wageningen UR (Wageningen, The Netherlands) and the University Medical Center Groningen (UMCG - Groningen, The Netherlands) join forces in PECTACEA a nutrition science company. PECTACEA leverages the expertise and resources of the Agrotechnology & Food Sciences Group (AFSG) at Wageningen UR and the medical expertise at the University Medical Center Groningen to identify natural inhibitors of galectin-3 that...

2012-08-30 02:25:41

PRINCETON, N.J., Aug. 30, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today the results of a Phase 1B clinical trial of an aluminum hydroxide (Alum) adjuvanted formulation of RiVax(TM), designed to improve the immunogenicity of the vaccine. The results of the Phase 1B study indicate that Alum adjuvanted RiVax(TM) is safe and well tolerated, and induces greater ricin neutralizing antibody levels in...